iBio, Inc. Form 10-Q Summary
Business context and reporting period
iBio, Inc. is a biotechnology company developing and commercializing the iBioLaunch platform for vaccines and therapeutic proteins and the iBioModulator platform for vaccine enhancement. Its strategy is to generate value through licensing, collaborations, service revenue, milestones and royalties.
This unaudited Form 10-Q covers the three months ended September 30, 2012, the first quarter of fiscal 2013, with comparative results for the three months ended September 30, 2011. The company reported 47,767,095 common shares outstanding as of November 14, 2012.
Financial performance and position
| Metric | Three months ended September 30, 2012 | Three months ended September 30, 2011 |
|---|---|---|
| Revenue | $390,186 | $320,348 |
| Research and development expense | $1,177,535 | $1,456,640 |
| General and administrative expense | $1,022,669 | $1,188,734 |
| Total operating expenses | $2,200,204 | $2,645,374 |
| Operating loss | $(1,810,018) | $(2,325,026) |
| Net loss (income) | $(2,051,427) | $383,143 |
| Basic and diluted loss per share | $(0.04) | $0.01 |
| Cash used in operating activities | $(1,290,337) | $(1,228,318) |
Revenue increased approximately 22% year over year and was generated from technology services provided to Fiocruz in connection with its yellow fever vaccine program. The operating loss improved by approximately $515,000 because expense reductions exceeded the increase in revenue. The filing does not present formal gross or operating margin measures; based on reported figures, the operating margin was approximately negative 464% in 2012 compared with negative 726% in 2011.
The company recorded a $240,883 non-cash expense from the change in fair value of a derivative financial liability, compared with $2,704,492 of non-cash income in the prior-year period. This valuation change was the principal reason the company moved from prior-year net income to a current-quarter net loss.
Cash was $4,276,373 at September 30, 2012, down from $5,624,403 at June 30, 2012. Total current assets were $5,151,369 and total liabilities were $3,419,867. Liabilities primarily comprised accounts payable of $2,418,996, accrued expenses of $240,263 and a derivative financial liability of $760,608. The filing does not identify conventional interest-bearing debt as a separate balance-sheet category.
Net cash used in investing activities was $57,693, consisting of additions to intangible assets. Net cash decreased by $1,348,030 during the quarter. Accumulated deficit was $33,389,208 at September 30, 2012.
Material changes versus the prior comparable period
- Revenue rose $69,838, or approximately 22%, primarily from the Fiocruz yellow fever vaccine services arrangement.
- Research and development expense declined $279,105, mainly because two FhCMB research projects had ended or were terminated. This reduction was partly offset by increased yellow fever project costs, related-party laboratory services and stock-based compensation.
- General and administrative expense declined $166,065, primarily because of lower professional fees.
- Stock-based compensation increased to $453,599 from $306,315. The company granted 1,070,000 options and 100,000 fully vested warrants during the quarter.
- The weighted-average basic share count increased to 47.8 million from 32.4 million, reflecting prior equity financing activity. Potential dilution included 27.6 million options and warrants excluded from diluted loss per share because they were anti-dilutive.
- The derivative liability increased from $519,725 at June 30, 2012 to $760,608 at September 30, 2012. Its valuation is sensitive to the company’s stock price, volatility, remaining term and other Black-Scholes assumptions.
Guidance, outlook, risks and unusual items
Management estimated that cash on hand at September 30, 2012 would fund operations through the end of the second calendar quarter of 2013. The company expected to fund subsequent development and commercialization through licensing or partnering receipts, milestones and royalties, and/or additional equity or debt financing. No quantified revenue or earnings guidance was provided.
The financial statements include a going-concern uncertainty. The company has incurred recurring losses and negative operating cash flow since its 2008 spin-off, and management stated that there is substantial doubt about its ability to continue as a going concern. Failure to obtain financing could require the company to delay, reduce or discontinue development, accept less favorable collaborations, relinquish technology rights or cease operations. Additional equity financing could materially dilute existing holders.
The company has a continuing Technology Transfer Agreement with FhCMB requiring payments of $2 million annually for five years beginning in November 2009, plus specified royalties and minimum annual payments. FhCMB-related research and development expense was approximately $550,000 in the quarter. A related-party vendor, whose minority stockholder is the company’s president, received approximately $95,000 for laboratory services during the quarter.
In July 2012, iBio announced a global alliance with GE Healthcare to commercialize its plant-based technologies. The filing describes the commercial framework but does not provide a quantified financial commitment or guaranteed revenue from the alliance. The Fiocruz agreement contemplates a $6.5 million investment to advance a yellow fever vaccine candidate through Phase 1 development, but future revenue and milestone realization remain uncertain.
Key risks include dependence on collaborators and licensees, uncertain product development and regulatory approval, protection and value of intellectual property, reliance on key personnel, financing needs, competition, potential impairment of intangible assets and possible future exchange-listing noncompliance. A prior NYSE Amex listing deficiency was reported as resolved in January 2012, but the company stated that future noncompliance cannot be ruled out.
Important facts for investors to verify
- Whether the company obtained financing or licensing proceeds after September 30, 2012 and whether liquidity extended beyond the projected second calendar quarter of 2013.
- The status, economics and revenue-recognition terms of the Fiocruz and GE Healthcare arrangements.
- The remaining payment obligations and royalty terms under the FhCMB Technology Transfer Agreement.
- The potential dilution from approximately 27.6 million outstanding options and warrants, including the anti-dilution warrant liability.
- Whether recurring operating losses and negative cash flow resulted in additional going-concern, exchange-listing or financing developments.
- The progress and regulatory status of the company’s vaccine and therapeutic candidates, including yellow fever, influenza and other platform programs.